1386 related articles for article (PubMed ID: 31942875)
1. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
2. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G
Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy.
Lamb YN
Am J Cardiovasc Drugs; 2021 Jan; 21(1):113-121. PubMed ID: 33469827
[TBL] [Abstract][Full Text] [Related]
6. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
7. A Statement on the Appropriate Administration of Tafamidis in Patients With Transthyretin Cardiac Amyloidosis.
Endo J; Sano M; Izumiya Y; Tsujita K; Nakamura K; Tahara N; Kuwahara K; Inomata T; Ueda M; Sekijima Y; Ando Y; Tsutsui H; Isobe M; Fukuda K
Circ J; 2019 Dec; 84(1):15-17. PubMed ID: 31735731
[TBL] [Abstract][Full Text] [Related]
8. Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).
Maurer MS; Elliott P; Merlini G; Shah SJ; Cruz MW; Flynn A; Gundapaneni B; Hahn C; Riley S; Schwartz J; Sultan MB; Rapezzi C;
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611125
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
10. Tafamidis for the treatment of transthyretin amyloidosis.
Lorenzini M; Elliott PM
Future Cardiol; 2019 Mar; 15(2):53-61. PubMed ID: 30767672
[TBL] [Abstract][Full Text] [Related]
11. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
12. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
Lamb YN; Deeks ED
Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
[TBL] [Abstract][Full Text] [Related]
13. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report.
Fujita T; Inomata T; Kaida T; Iida Y; Ikeda Y; Nabeta T; Ishii S; Maekawa E; Naruke T; Koitabashi T; Kitamura E; Sekijima Y; Ako J
Cardiology; 2017; 137(2):74-77. PubMed ID: 28152524
[TBL] [Abstract][Full Text] [Related]
15. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
16. Therapy of ATTR Cardiac Amyloidosis: Current Indications.
Di Lisi D; Di Stefano V; Brighina F; Galassi AR; Novo G
Curr Probl Cardiol; 2023 Feb; 48(2):101487. PubMed ID: 36336119
[TBL] [Abstract][Full Text] [Related]
17. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
[TBL] [Abstract][Full Text] [Related]
18. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
[TBL] [Abstract][Full Text] [Related]
19. Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid.
Tsai FJ; Jaeger M; Coelho T; Powers ET; Kelly JW
Amyloid; 2023 Sep; 30(3):279-289. PubMed ID: 36691999
[TBL] [Abstract][Full Text] [Related]
20. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
